Banyan Biomarkers Announces Issuance of U.S. Patent for Biomarkers for Traumatic Injury

Share Article

Banyan Biomarkers, Inc. announced today that the U.S. Patent and Trademark Office has granted U.S. Patent No. 7,456,027, “Proteolytic Biomarkers for Traumatic Injury to the Nervous System”, licensed exclusively by Banyan Biomarkers from the University of Florida with the company as co-inventor. This newly issued patent describes a method of determining the presence of neural injury through the measurement of proteolytic breakdown products of microtubule-associated proteins (MAP). The company has developed Enzyme Linked Immunosorbent Assays (ELISAs) that detect MAP and is conducting a clinical study designed to evaluate MAP as an indicator of traumatic brain injury (TBI). The company’s goal is to seek FDA regulatory review for the use of MAP as an aid in the detection and monitoring of TBI.

Detection of Spectrin and Spectrin Proteolytic Cleavage Products in Assessing Nerve Cell Damage

Gary Ascani, Chief Executive Officer of Banyan Biomarkers, Inc., commented, "We are very pleased with the addition of this patent to Banyan's intellectual property portfolio of TBI biomarkers. With nearly 2 million people experiencing TBI annually in the United States and no available point-of-care diagnostic test, Banyan is paving the way in establishing the leadership position in the discovery, validation and development of products for the detection of traumatic brain injury."

Banyan Biomarkers also has exclusive licenses from the University of Florida for U.S. Patent no. 7,291,710 "Detection of Spectrin and Spectrin Proteolytic Cleavage Products in Assessing Nerve Cell Damage" and U.S. Patent No. 7,396,654 "Neural Proteins as Biomarkers for Traumatic Brain Injury."

To learn more about Banyan Biomarkers, Inc., visit http://www.banyanbio.com/.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Gary Ascani
Visit website